| Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia M Taparia, FT Cordingley, MF Leahy European journal of haematology 68 (5), 307-309, 2002 | 89 | 2002 |
| Risk factors for post‐transplant lymphoproliferative disorder after Thymoglobulin‐conditioned hematopoietic cell transplantation A Kalra, C Roessner, J Jupp, T Williamson, R Tellier, A Chaudhry, F Khan, ... Clinical Transplantation 32 (1), e13150, 2018 | 26 | 2018 |
| Results from a phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate, or high risk, relapsed/refractory myelofibrosis N Pemmaraju, V Gupta, H Ali, A Yacoub, ES Wang, S Lee, GJ Schiller, ... Blood 134, 558, 2019 | 25 | 2019 |
| Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder A Kalra, C Roessner, J Jupp, T Williamson, R Tellier, A Chaudhry, F Khan, ... Cytotherapy 20 (5), 706-714, 2018 | 24 | 2018 |
| Avapritinib versus placebo in indolent systemic mastocytosis J Gotlib, M Castells, HO Elberink, F Siebenhaar, K Hartmann, ... NEJM evidence 2 (6), EVIDoa2200339, 2023 | 19 | 2023 |
| Validation of the HScore and the HLH‐2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort L Bilston, J Croden, M Taparia, M Karkhaneh, J Grossman, H Sun European Journal of Haematology 109 (2), 129-137, 2022 | 17 | 2022 |
| Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML) MM Patnaik, H Ali, V Gupta, G Schiller, S Lee, A Yacoub, M Talpaz, ... Liver 4, 20, 2019 | 15 | 2019 |
| Detection of hairy cell leukaemia in blood and bone marrow using multidimensional flow cytometry with CD45‐PECy5 and SS gating L Tytherleigh, M Taparia, MF Leahy Clinical & Laboratory Haematology 23 (6), 385-390, 2001 | 10 | 2001 |
| A Phase 1/2 Study of single agent Tagraxofusp, a first-in-class CD123-targeted therapy, in patients with myelofibrosis that is relapsed/refractory following JAK inhibitor therapy A Yacoub, MM Patnaik, H Ali, ES Wang, V Gupta, S Lee, GJ Schiller, ... Blood 138, 140, 2021 | 9 | 2021 |
| Results from ongoing phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia MM Patnaik, V Gupta, JR Gotlib, HE Carraway, M Wadleigh, GJ Schiller, ... Blood 128 (22), 4245, 2016 | 9 | 2016 |
| A multicenter phase 1/2 clinical trial of tagraxofusp, a CD123-targeted therapy, in patients with poor-risk primary and secondary myelofibrosis N Pemmaraju, V Gupta, H Ali, A Yacoub, ES Wang, S Lee, GJ Schiller, ... Blood 136, 39-40, 2020 | 8 | 2020 |
| Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. N Pemmaraju, H Ali, V Gupta, GJ Schiller, S Lee, A Yacoub, M Talpaz, ... Journal of Clinical Oncology 37 (15_suppl), 7058-7058, 2019 | 7 | 2019 |
| MPN-377: updated results from a phase 1/2 clinical trial of tagraxofusp, a CD123-targeted therapy, in patients with poor-risk myelofibrosis N Pemmaraju, V Gupta, H Ali, A Yacoub, E Wang, S Lee, G Schiller, ... Clinical Lymphoma Myeloma and Leukemia 20, S338-S339, 2020 | 5 | 2020 |
| Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia L Saini, J Brandwein, R Turner, L Larratt, M Hamilton, A Peters, C Wu, ... Leukemia Research 45, 47-52, 2016 | 5 | 2016 |
| Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review J Croden, L Bilston, M Taparia, J Grossman, HL Sun Annals of Hematology 101 (10), 2297-2306, 2022 | 4 | 2022 |
| Incidence of bleeding and thromboembolism and impact on overall survival in adult patients with hemophagocytic lymphohistiocytosis: A 20‐year provincial retrospective cohort study J Croden, L Bilston, M Taparia, J Grossman, HL Sun Journal of Thrombosis and Haemostasis 20 (3), 671-683, 2022 | 3 | 2022 |
| An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia JM Brandwein, D Hallett, M Karkhaneh, N Zhu, E Liew, L Bolster, ... American journal of hematology 96 (1), E17-E20, 2021 | 2 | 2021 |
| AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies N Pammaraju, H Kantarjian, K Sweet, ES Wang, AA Lane, H Ali, AS Stein, ... Clinical Lymphoma Myeloma and Leukemia 22, S246-S247, 2022 | 1 | 2022 |
| MPN-379: Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML) M Patnaik, H Ali, A Yacoub, V Gupta, S Lee, E Wang, G Schiller, C Brooks, ... Clinical Lymphoma Myeloma and Leukemia 20, S339, 2020 | 1 | 2020 |
| POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial J Gotlib, M Castells, HO Elberink, F Siebenhaar, K Hartmann, ... Clinical Lymphoma Myeloma and Leukemia 23, S194, 2023 | | 2023 |
